CN113559268A - Antifungal medicine composition - Google Patents
Antifungal medicine composition Download PDFInfo
- Publication number
- CN113559268A CN113559268A CN202110930923.7A CN202110930923A CN113559268A CN 113559268 A CN113559268 A CN 113559268A CN 202110930923 A CN202110930923 A CN 202110930923A CN 113559268 A CN113559268 A CN 113559268A
- Authority
- CN
- China
- Prior art keywords
- antifungal
- pharmaceutical composition
- inositol
- myo
- methoxybenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 230000000843 anti-fungal effect Effects 0.000 title claims abstract description 21
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims abstract description 16
- 229960000367 inositol Drugs 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 241000222122 Candida albicans Species 0.000 claims abstract description 12
- 229940095731 candida albicans Drugs 0.000 claims abstract description 12
- 239000003429 antifungal agent Substances 0.000 claims abstract description 8
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical group C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 12
- 229960004884 fluconazole Drugs 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 241001337994 Cryptococcus <scale insect> Species 0.000 claims description 6
- 241000555688 Malassezia furfur Species 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 claims description 4
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 4
- 108010020326 Caspofungin Proteins 0.000 claims description 4
- 229960003204 amorolfine Drugs 0.000 claims description 4
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 4
- 229960003942 amphotericin b Drugs 0.000 claims description 4
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 claims description 4
- 229960003034 caspofungin Drugs 0.000 claims description 4
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004413 flucytosine Drugs 0.000 claims description 4
- 229960004130 itraconazole Drugs 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 4
- 229960002722 terbinafine Drugs 0.000 claims description 4
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 4
- 229960004740 voriconazole Drugs 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007902 hard capsule Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241000779599 Malpighia Species 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000857964 Ileodictyon cibarium Species 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 2
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000037026 Invasive Fungal Infections Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 206010052366 systemic mycosis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an antifungal medicine composition. Experiments prove that the compound D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol combined antifungal drug has the effect of obviously inhibiting drug-resistant candida albicans. The application provided by the invention has good medicinal value and application prospect.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an antifungal medicine composition consisting of D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol and an antifungal medicine.
Background
Invasive mycosis refers to systemic infectious diseases caused by invasion of tissues, organs and blood by various pathogenic candida, and the most common pathogenic bacteria include candida albicans, candida tropicalis, candida glabrata and candida kininogenes. Most life-threatening fungal infections occur in immunocompromised trauma, high immunosuppressive usage, neutropenia, medical device implantation and organ transplant patients with a mortality rate of about 40%. With the intervention treatment of antibacterial drugs such as fluconazole, the clinical isolate produces drug resistance genes and forms cross resistance with other azole drugs. Making the treatment of invasive mycoses problematic. The inventor finds that inositol has no antifungal effect in screening medicines, but unexpectedly finds that the derivative D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol has a good synergistic antibacterial effect on drug-resistant Candida albicans, which is the first discovery.
Disclosure of Invention
The invention aims to provide an antifungal medicine composition consisting of D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol and an antifungal medicine, wherein the structural formula of the D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol is shown in the specification
。
The antifungal drug is fluconazole, voriconazole, itraconazole, amphotericin B, caspofungin, flucytosine, terbinafine and amorolfine.
The mass ratio of the D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol to the antifungal drug is 5: 1.
the fungi are Candida albicans, Marneffei basket fungus, Cryptococcus and Malassezia furfur.
The fungi are Candida albicans resistant strain, Marneffei basket fungus resistant strain, Cryptococcus resistant strain, and Malassezia furfur resistant strain.
The dosage forms of the medicine are tablets, hard capsules, soft capsules, powder, pills and granules.
The dosage forms of the medicine are solution injection, suspension injection, emulsion injection and sterile powder for injection.
The invention has the advantages that:
the invention has the advantages and positive effects that sufficient chemical and pharmacological basis is provided for drug candidates for treating drug-resistant deep fungal infections.
Detailed Description
The present invention is further illustrated but not limited in any way by the following examples, and any modifications made thereto are intended to fall within the scope of the present invention.
D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol
An antifungal pharmaceutical composition comprising the antifungal medicine and antifungal medicine.
The antifungal drug is fluconazole, voriconazole, itraconazole, amphotericin B, caspofungin, flucytosine, terbinafine and amorolfine.
The mass ratio of the D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol to the antifungal drug is 5: 1.
the fungi are Candida albicans, Marneffei basket fungus, Cryptococcus and Malassezia furfur.
The fungi are Candida albicans resistant strain, Marneffei basket fungus resistant strain, Cryptococcus resistant strain, and Malassezia furfur resistant strain.
The dosage forms of the medicine are tablets, hard capsules, soft capsules, powder, pills and granules.
The dosage forms of the medicine are solution injection, suspension injection, emulsion injection and sterile powder for injection. The antifungal drug is fluconazole, voriconazole, itraconazole, amphotericin B, caspofungin, flucytosine, terbinafine and amorolfine.
Example 1
D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol antifungal activity test:
materials and methods
Medicine and sample
The preparation method of the D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol comprises the following steps:
reference is made to the following documents (J. Org. Chem.1996, 61, 23, 8016-application 8023) to obtain D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol.
The sample D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol was dissolved to 100mg/ml and placed in a refrigerator at 4 ℃. Grinding fluconazole, dissolving with DMSO, ultrasonic treating for 10min, centrifuging to obtain supernatant, storing at 50mg/ml, and placing in refrigerator at 4 deg.C.
II, reagent and solution
(1) Reagent
Fluconazole, DMSO
(2) Culture medium
Sabouraud's liquid culture medium
Third, Experimental methods
Taking a 96-well culture plate, diluting the positive drug fluconazole into an initial concentration of 200ug/ml, directly using a storage solution for a sample, directly adding 200ug/ml fluconazole into the storage solution for the sample during drug combination, then diluting by 5 times, carrying out 4 concentration gradients, and repeating 3 wells for each concentration gradient. Adding fungus suspension into each well, wherein the concentration of Candida albicans standard strain is 1 × 105CFU/mL, concentration of Candida albicans resistant strain 1 × 105 CFU/mL, cultured at 37 ℃ for 24 h. The OD value at 630nm was measured by a microplate reader. The experiment was also set with a medium blank control, a bacteria solution control and a fluconazole positive drug control.
Fourth, calculation formula
Fungal activity inhibition (%) = (1-sample OD value/Experimental control hole OD value) × 100%
Combination Index (FICI): FICI = MICA/A + MICB/B (where A and B are MIC values for single use of the two drugs, respectively, and MICA and MICB are MIC values for combination of the two drugs, respectively.) when the MIC values are higher than the detection upper limit, a value twice the upper limit concentration is used to calculate the FICI. the MIC50 value in this experiment is calculated as the percentage inhibition of fluconazole at 50% minimal fungal growth. when FICI is less than or equal to 0.5, the two drugs act in a synergistic manner, when FICI is greater than 0.5 and less than or equal to 4, the two drugs act in an unrelated manner, and when FICI is greater than 4, the two drugs act in an antagonistic manner.
The results of the experiments are shown in the following table.
Experimental results show that the D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol and the antifungal drug fluconazole are combined to have an inhibiting effect on candida albicans resistant bacteria and have a strong synergistic effect.
Claims (7)
1. An antifungal medicine composition is characterized by consisting of D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol and an antifungal medicine, wherein the structural formula of the D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol is shown in the specification
。
2. The antifungal pharmaceutical composition of claim 1 wherein the antifungal agent is fluconazole, voriconazole, itraconazole, amphotericin B, caspofungin, flucytosine, terbinafine and amorolfine.
3. The antifungal pharmaceutical composition of claim 1 wherein the mass ratio of D-1-O- (4-methoxybenzyl) -2,3,4, 5-tetra-O-benzyl-myo-inositol to antifungal is 5: 1.
4. the antifungal pharmaceutical composition of claim 1 wherein the fungus is selected from the group consisting of candida albicans, malpighia marneffei, cryptococcus and malassezia furfur.
5. The antifungal pharmaceutical composition of claim 1 wherein the fungus is a Candida albicans resistant strain, a Marneffei staphylium resistant strain, a Cryptococcus resistant strain, a Malassezia furfur resistant strain.
6. The antifungal pharmaceutical composition of claim 1, wherein the dosage form of the drug is tablet, hard capsule, soft capsule, powder, pill, granule.
7. The antifungal pharmaceutical composition of claim 6, wherein the pharmaceutical composition is in the form of solution injection, suspension injection, emulsion injection, or sterile powder for injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110930923.7A CN113559268A (en) | 2021-08-13 | 2021-08-13 | Antifungal medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110930923.7A CN113559268A (en) | 2021-08-13 | 2021-08-13 | Antifungal medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113559268A true CN113559268A (en) | 2021-10-29 |
Family
ID=78171619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110930923.7A Pending CN113559268A (en) | 2021-08-13 | 2021-08-13 | Antifungal medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113559268A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989612A (en) * | 1996-10-11 | 1999-11-23 | Rodia Inc. | Foods including antimycotic agent |
| CN1446870A (en) * | 2002-03-27 | 2003-10-08 | 馨乐丽康野田株式会社 | Natural paint and its producing process |
-
2021
- 2021-08-13 CN CN202110930923.7A patent/CN113559268A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989612A (en) * | 1996-10-11 | 1999-11-23 | Rodia Inc. | Foods including antimycotic agent |
| CN1446870A (en) * | 2002-03-27 | 2003-10-08 | 馨乐丽康野田株式会社 | Natural paint and its producing process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103536613B (en) | A kind of antifungal pharmaceutical composition | |
| Kauffman et al. | Update on echinocandin antifungals | |
| CN109154603A (en) | For treating the dosage regimen of fungal infection | |
| CN110769854B (en) | Antifungal agents for use in combination | |
| Madhavan et al. | In vitro activity of fluconazole and voriconazole against clinical isolates of Candida spp. by E-test method. | |
| BR112020002290A2 (en) | methods of treating a fungal infection in an individual in need of it, of preventing a fungal infection in an individual, and of treating infection by vulvovaginal candidiasis (vvc) in an individual in need of it | |
| CN101723980A (en) | Triazole derivate used for treatment | |
| JP6254597B2 (en) | Pharmaceutical composition for diseases caused by pathogenic microorganisms such as Candida | |
| CN113559268A (en) | Antifungal medicine composition | |
| CN113559087A (en) | Antifungal medicine composition composed of 3,4-di-O-benzyl phytosphingosine and antifungal medicine | |
| CN113476610A (en) | Antifungal medicine composition composed of glycerin derivative and antifungal medicine | |
| CN108478566A (en) | Application and products thereof of the butylphenyl phthaleine in preparing antifungal products | |
| EP2650285A1 (en) | Fungicide | |
| KR20230024375A (en) | Compounds and methods for treating fungal infections | |
| CA3110860A1 (en) | Compounds and methods for treating fungal infections | |
| CN113332277B (en) | Application of diketopyrrolopyrrole compound in preparation of antifungal drugs | |
| CN111297856B (en) | Medicinal composition for resisting fungal infection and application thereof | |
| CN113318107B (en) | Application of nitrogen-containing compound in preparation of antifungal medicine | |
| CN113456641B (en) | Application of compound in preparation of antifungal medicine | |
| CN111084885B (en) | Antifungal medicine composition consisting of lignans active molecules SWL-1 and antifungal medicine | |
| KR102683355B1 (en) | Antifungal drugs used in combination | |
| CN103565794A (en) | Application of 7-hydroxy-4'-methoxyisoflavone in antifungal medicament | |
| CN103585143A (en) | Application of formononetin in preparation of aspergillus fumigatus resistant medicament | |
| CN103356626B (en) | Use of pyrazolopyrimidine compound in treatment on trichophyton rubrum-infected diseases | |
| CN103417545B (en) | Application of pyrazolopyrimidine compound in preparing medicines for aspergillus fumigatus infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211029 |
|
| RJ01 | Rejection of invention patent application after publication |